Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Douglas R. Adkins et al.|The Lancet Oncology|2021Cited by 257
A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinomaMichael J. Dennis, Kathryn A. Gold, Assuntina G. Sacco et al.|Oral Oncology|2022Cited by 21